Status:
COMPLETED
A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Takeda
Conditions:
Carcinoma, Non-Small-Cell Lung
Anaplastic Lymphoma Kinase
Eligibility:
All Genders
18+ years
Brief Summary
The aims of the study are to assess the safety profile of brigatinib and the clinical response rates in adults with Anaplastic Lymphoma Kinase (ALK)-Positive Metastatic Non Small Cell Lung Cancer (NSC...
Detailed Description
This is a prospective, observational post-marketing surveillance study of brigatinib in participants with advanced or metastatic NSCLC. This study will assess the safety, efficacy and effectiveness of...
Eligibility Criteria
Inclusion
- 1\. With either a diagnosis of ALK positive metastatic NSCLC previously treated with crizotinib OR a diagnosis of ALK positive metastatic NSCLC previously not treated with an ALK inhibitor. Have received at least one dose of brigatinib according to approved indications.
Exclusion
- Note: There are no specific exclusion criteria.
Key Trial Info
Start Date :
December 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2023
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT04887519
Start Date
December 30 2020
End Date
March 31 2023
Last Update
April 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IC Projects
Buenos Aires, Argentina, C1055AAD